UBS Group
GLMD icon

UBS Group’s Galmed Pharmaceuticals GLMD Stock Holding History

UBS Group’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-318
Closed -$1.58K – 10370
2026
Q1 		$1.25K Buy
318
+91
+40% +$491 ﹤0.01% 9571
2025
Q4 		$1.36K Buy
227
+107
+89% +$1K ﹤0.01% 9613
2025
Q3 		$1.33K Sell
120
-743
-86% -$9.55K ﹤0.01% 9374
2025
Q2 		$12.7K Buy
863
+725
+525% +$8.53K ﹤0.01% 8726
2025
Q1 		$1.59K Sell
138
-702
-84% -$13.8K ﹤0.01% 9484
2024
Q4 		$21.4K Buy
840
+182
+28% +$4.93K ﹤0.01% 7823
2024
Q3 		$36.1K Buy
658
+655
+21,833% +$22.9K ﹤0.01% 7031
2024
Q2 		$77 Sell
3
-21
-88% -$737 ﹤0.01% 9195
2024
Q1 		$782 Buy
+24
New +$865 ﹤0.01% 8362
2023
Q4 		– Hold
0
– -$17 – 9526
2023
Q3 		– Hold
0
– – – 9149
2023
Q2 		– Sell
-3
Closed -$1.3K – 8783
2023
Q1 		$1.83K Sell
3
-12
-80% -$10.3K ﹤0.01% 8635
2022
Q4 		$10.7K Sell
15
-4
-21% -$2.1K ﹤0.01% 8474
2022
Q3 		$8K Buy
19
+15
+375% +$10.2K ﹤0.01% 8712
2022
Q2 		$4K Buy
+4
New +$5.3K ﹤0.01% 9067
2022
Q1 		– Sell
-4
Closed -$12K – 10487
2021
Q4 		$12K Buy
+4
New +$14.4K ﹤0.01% 8555
2021
Q3 		– Hold
0
– – – 9742
2021
Q2 		– Sell
-2
Closed -$12K – 9525
2021
Q1 		$12K Sell
2
-5
-71% -$27.7K ﹤0.01% 7790
2020
Q4 		$32K Buy
+7
New +$35K ﹤0.01% 6573
2020
Q3 		– Hold
0
– -$3K – 8151
2020
Q2 		– Sell
-2
Closed -$13.5K – 7535
2020
Q1 		$12K Buy
2
+1
+100% +$7.6K ﹤0.01% 6819
2019
Q4 		$4K Buy
+1
New +$6.87K ﹤0.01% 7658
2019
Q3 		– Sell
-1
Closed -$9K – 8094
2019
Q2 		$9K Buy
+1
New +$10.3K ﹤0.01% 7125
2019
Q1 		– Hold
0
– -$4K – 7872
2018
Q4 		– Sell
-25
Closed -$349K – 7628
2018
Q3 		$488K Hold
25
– – ﹤0.01% 4428
2018
Q2 		$426K Sell
25
-3
-11% -$34.7K ﹤0.01% 4442
2018
Q1 		$223K Buy
28
+27
+2,700% +$315K ﹤0.01% 4713
2017
Q4 		$7K Buy
+1
New +$11.8K ﹤0.01% 7224
2017
Q3 		– Sell
-5
Closed -$48K – 7825
2017
Q2 		$48K Buy
+5
New +$37.7K ﹤0.01% 5672
2017
Q1 		– Hold
0
– – – 7762
2016
Q4 		– Sell
-3
Closed -$15.8K – 7862
2016
Q3 		$17K Buy
+3
New +$18.1K ﹤0.01% 6428
2016
Q2 		– Hold
0
– -$3K – 7814
2016
Q1 		– Sell
-3
Closed -$23.5K – 7192
2015
Q4 		$35K Buy
3
+2
+200% +$25.5K ﹤0.01% 6177
2015
Q3 		$12K Buy
+1
New +$13.2K ﹤0.01% 7146
2015
Q2 		– Sell
-3
Closed -$41.7K – 8066
2015
Q1 		$37K Buy
3
+2
+200% +$24K ﹤0.01% 6324
2014
Q4 		$9K Buy
+1
New +$8.69K ﹤0.01% 8478

Other funds holding GLMD

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

UBS Group's GLMD Position: Q2 2026 in Review

UBS Group sold out of Galmed Pharmaceuticals (GLMD) in Q2 2026, closing a stake of 318 shares — an estimated $1.58K sold.

UBS Group first reported a position in GLMD in Q4 2014 and held it in 29 quarters. The position peaked at $488K in Q3 2018. 11 funds tracked by Wall St. Rank hold GLMD as of Q2 2026.

  • UBS Group reported no remaining Galmed Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • UBS Group sold 318 Galmed Pharmaceuticals shares in Q2 2026, an estimated $1.58K.
  • UBS Group first reported a position in Galmed Pharmaceuticals in Q4 2014 and held it in 29 quarters.
  • UBS Group's Galmed Pharmaceuticals position peaked at $488K in Q3 2018.
  • 11 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.